ARS Pharmaceuticals, Inc. Class Action Lawsuit - SPRY

Company
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)
Lead Plaintiff Deadline
October 5, 2026 (52 Days Left)
Class Period
March 9, 2026 - June 24, 2026

52
Days Left

Lead Plaintiff Deadline

Oct 5, 2026

Join the ARS Pharmaceuticals, Inc. Class Action Lawsuit

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Fill in below.

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

1.I have reviewed a complaint filed in the action.

2.I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.

3.I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.

4.My transaction(s) in which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.

5.Within the last 3 years,

6.I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against ARS Pharmaceuticals, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. On June 24, 2026, after the market closed, ARS published a press release announcing that the Company did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, investors and analysts reacted immediately to ARS’s revelation. The price of ARS’s common stock declined from a closing market price of $10.54 per share on June 24, 2026 to $8.02 per share on June 25, 2026, a decline of over 23.9% in the span of just a single day.

Eligibility

In order to be eligible to join the SPRY class action lawsuit, you must have incurred a loss on shares of ARS Pharmaceuticals purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in ARS Pharmaceuticals during the relevant time frame or pursuant to the relevant offering(s), you have until October 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

ARS Pharmaceuticals, Inc Class Action Lawsuit Details

Key Facts About ARS Pharmaceuticals Inc. (NASDAQ: SPRY)

●        The Allegation: The complaint alleges ARS Pharmaceuticals Inc. misled investors about the expected timeline for expanded insurance coverage for neffy through CVS Caremark. Defendants allegedly expressed confidence that coverage would begin on July 1, 2026 and support the summer and back-to-school allergy seasons, while failing to disclose timeline risks.

●        The Stock Drop: SPRY fell $2.52 per share, over 23.9%, to $8.02 per share on June 25, 2026, after ARS announced that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle.

●        Class Period & Defendants: The class period runs from March 9, 2026 through June 24, 2026, inclusive. The named defendants are ARS Pharmaceuticals Inc., Richard E. Lowenthal (Co-Founder, President, Chief Executive Officer, and Director), and Eric Karas (Chief Commercial Officer).

●        Lead Plaintiff Deadline: October 5, 2026. Investors who wish to seek appointment as lead plaintiff must apply by the deadline.

ARS Pharmaceuticals Class Action Summary

Company

ARS Pharmaceuticals Inc. (NASDAQ: SPRY)

Lead Plaintiff Deadline

October 5, 2026

Class Period

March 9, 2026 - June 24, 2026

Stock Drop

June 25, 2026 - SPRY fell $2.52 (over 23.9%) to $8.02

Introduction

A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. and certain executives. The lawsuit covers investors who purchased or otherwise acquired ARS common stock from March 9, 2026 through June 24, 2026.

The complaint alleges defendants made materially false and misleading statements about neffy's CVS Caremark coverage timeline. ARS had told investors it expected expanded coverage by July 1, 2026.

After the market closed on June 24, 2026, ARS said no new coverage decision had been issued. SPRY fell over 23.9% the next trading day, according to the complaint.

Company Profile

ARS Pharmaceuticals Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy, a needle-free intranasal epinephrine product for emergency treatment of Type 1 allergic reactions, including anaphylaxis. The company is headquartered in San Diego, California.

Class Period

March 9, 2026 – June 24, 2026

Investors who purchased or acquired ARS Pharmaceuticals Inc. (SPRY) securities during the Class Period may be eligible to seek recovery under federal securities laws.

Allegations

The ARS Pharmaceuticals securities lawsuit centers on neffy, the company's needle-free intranasal epinephrine product. According to the complaint, defendants told investors that expanded access through CVS Caremark was a key part of neffy's commercialization strategy, because prior authorization requirements created administrative friction that could limit prescribing momentum.

On March 9, 2026, ARS issued a press release announcing fourth quarter and full year 2025 results. Defendant Richard E. Lowenthal stated that progress with insurers had been positive and that ARS remained focused on securing unrestricted access with the remaining major payors. During the same day's earnings call, he said the company was committed to expanding unrestricted coverage with CVS Caremark, where discussions were ongoing, and stated that Caremark would wait until July 1 because it had a rigid system.

Also on March 9, 2026, Defendant Eric Karas told investors that ARS was highly focused on CVS Caremark, Anthem, and large regional payers to ensure commercial coverage without restrictions. He said the company was encouraged by ongoing payer discussions and expected to share more information during the second quarter as those discussions progressed.

The complaint alleges these statements became more specific on May 15, 2026, when ARS reported first quarter 2026 results. Lowenthal stated that, based on feedback from CVS in late April, ARS had submitted an updated proposal to add neffy to commercial formularies, remove the prior authorization requirement, and target a July 1 effective date. Karas also stated that the CVS Caremark proposal was in the final stages of the approval process and that the company expected to share more in the weeks to come. Plaintiffs allege defendants knew or recklessly disregarded that the CVS Caremark timeline could be significantly delayed, and failed to disclose the risk that expanded coverage would not be available by July 1, 2026 for the summer and back-to-school allergy seasons.

The Truth Emerges

The alleged truth emerged after the market closed on June 24, 2026, when ARS issued a press release providing an update on payer access for neffy. The company stated that, despite payer discussions continuing until mid-June, no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle.

That disclosure contradicted the prior narrative that a CVS Caremark formulary addition was nearing completion and targeted for July 1, according to the complaint. ARS also stated that demand had continued to grow independent of additional coverage additions, and that Florida would add neffy to its unrestricted Medicaid formulary effective July 1, 2026.

Analysts reacted to the disclosure as a meaningful setback. The complaint cites a June 25, 2026 William Blair report stating that the announcement came as a negative shock given management's prior guidance and updates suggesting positive progress on the contract. The report also stated that missing the July 1 formulary update meant neffy would not be on formulary with CVS for that year's back-to-school season.

Market Reaction

Following the June 24, 2026 disclosure, investors and analysts reacted immediately, according to the complaint. ARS common stock declined from a closing price of $10.54 per share on June 24, 2026 to $8.02 per share on June 25, 2026, a drop of $2.52 per share, or over 23.9%, in one day.

The complaint alleges the drop reflected the market's reassessment of neffy's commercialization outlook after the CVS Caremark coverage expansion did not occur by the guided July 1, 2026 deadline. Plaintiffs claim the prior artificial inflation came out of SPRY's stock price when investors learned that expanded insurance coverage would not be in place for the summer and back-to-school allergy seasons.

Next Steps

●        Lead Plaintiff Deadline: October 5, 2026

●        After the lead plaintiff deadline, the Court will consider any lead plaintiff motions.

●        Defendants may file a motion to dismiss.

●        If the case proceeds, the Court may later consider class certification. .

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. Prior results do not guarantee similar outcomes.

Deadline
Oct 5, 2026

Get Started